What Patients Need to Know About the GLP-1 FDA Policy Changes
April 30, 2025 | ABCS
Medications such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound™) belong to a class called glucagon-like peptide-1 (GLP-1) receptor agonists. Originally FDA-approved for type 2 diabetes, several now carry indications for weight management and cardiovascular risk reduction. Explosive demand, and the resulting shortage of the drugs, led the FDA to… Read More »